response2/2

One page each with one reference each, peer response with an answer to the question they pose in their discussion.

PEER 1

FDA Drug Recall: Rheumacare Capsules

One recent FDA recall that stood out to me involved Rheumacare Capsules, manufactured by Virgo UAP Pharma and distributed by Handelnine Global Limited (d/b/a Navafresh). This product was recalled nationwide due to elevated levels of lead, which is particularly concerning given the serious health risks associated with lead exposure. Chronic lead exposure can result in neurological impairment, kidney damage, gastrointestinal symptoms, and developmental concerns, especially in children, pregnant individuals, and older adults (U.S. Food and Drug Administration [FDA], 2025a).

What makes this recall especially concerning is that Rheumacare is marketed for rheumatologic and pain-related conditions, meaning patients may be taking it regularly or long-term. This increases the risk for cumulative toxicity. It also highlights an ongoing issue in clinical practice, as patients often do not consider supplements or non-prescription products to be medications and may not report them unless specifically asked.

Question for classmates:

What strategies do you plan to use as a nurse practitioner to ensure patients disclose supplement or alternative medication use so potential safety risks can be identified early?

Newly FDA-Approved Medication: Jascayd (nerandomilast)

A recent FDA approval that represents a major advancement in care is Jascayd (nerandomilast), which was approved in 2025 for the treatment of idiopathic pulmonary fibrosis (IPF). IPF is a progressive and debilitating lung disease characterized by fibrosis of the alveoli, leading to worsening shortness of breath, declining lung function, and reduced quality of life. Prior to this approval, there had been no new treatment options approved for IPF in more than a decade (FDA, 2025b).

Jascayd is a phosphodiesterase-4 (PDE4) inhibitor. Its mechanism of action involves reducing inflammatory signaling pathways that contribute to lung fibrosis. Clinical trials demonstrated that patients treated with Jascayd experienced a significantly smaller decline in forced vital capacity (FVC) compared to placebo, indicating slower disease progression (FDA, 2025b).

The recommended dosage is 18 mg taken orally twice daily, approximately 12 hours apart, with or without food. For patients who experience intolerance, the dosage may be reduced to 9 mg twice daily. Common adverse effects include diarrhea, nausea, decreased appetite, weight loss, fatigue, headache, dizziness, depression, and upper respiratory infections. Drugâ€“drug interactions must also be considered, particularly with strong CYP3A inhibitors or inducers, which may require dosage adjustment or avoidance.

From a nurse practitioner perspective, this medication highlights the importance of patient education, routine monitoring for adverse effects such as mood changes and weight loss, and thorough medication reconciliation. Given the complexity of IPF and the vulnerability of this patient population, close follow-up and clear communication are essential to promote safe and effective treatment.

References

U.S. Food and Drug Administration. (2025a). Handelnine Global Limited d/b/a Navafresh issues nationwide recall of Rheumacare capsules due to elevated lead levels. https://www.fda.govLinks to an external site.

U.S. Food and Drug Administration. (2025b). FDA approves drug to treat idiopathic pulmonary fibrosis. https://www.fda.govLinks to an external site.

PEER 2

Medication Safety and Drug Approvals

Anthony Trinh 123 Herbals LLC issued a nationwide recall of Silintan Capsules on January 7th, 2026. The dietary supplement drug was withdrawn due to the presence of undeclared meloxicam. The Food and Drug Administration (FDA) posted the company’s announcement to increase awareness in the drug market. Silintan capsules were marketed as a source of relief for joint and body aches. Meloxicam is an approved Nonsteroidal Anti-Inflammatory Drug (NSAID) used for the management of osteoarthritis pain (Food and Drug Administration, 2026). According to the FDA, drugs containing meloxicam cannot be advertised as dietary supplements. The presence of Meloxicam rendered the drugs unapproved for safety and efficacy, leading to the recall. Exposure to high doses of meloxicam poses life-threatening concerns such as stroke and heart attack. Patients using the drug face risks of ulcerations, kidney issues, and gastrointestinal bleeding. The recall recommended discarding the drugs or returning them to the seller.

Question

How can a nurse practitioner protect patients from harm associated with Silintan capsules that contain meloxicam?

Mitapivat Tablets

The FDA approved its first oral treatment for anemia, an inherited blood disorder. The Aqvesme tablets are effective in the treatment of anemia in adults with beta or alpha thalassemia. The drug is the first oral treatment for beta-thalassemia and the first drug for alpha-thalassemia. The recommended dosage is 100 mg twice daily, with or without food. Notably, Mitapivat is a pyruvate kinase activator that acts by binding to the pyruvate kinase enzyme and increasing its activity (FDA, 2026). An imbalance in the globin production results in increased oxidative stress. The oxidative stress leads to ineffective hemolysis and erythropoiesis. Treatment with the drug is intended to be long-term; patients are required to discontinue treatment if no benefits are observed. In conclusion, patients should observe the efficacy and safety of the drug in their long-term usage.

References

Food and Drug Administration (FDA). (2026). Anthony Trinh, 123Herbals LLC (123HERBALS.COM) Issues Nationwide Recall of Silintan Capsules Due to the Presence of Undeclared Meloxicam. Recalls, Market Withdrawals, and Safety Alerts.https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/anthony-trinh-123herbals-llc-123herbalscom-issues-nationwide-recall-silintan-capsules-due-presenceLinks to an external site.

Food and Drug Administration (FDA). (2026). FDA approves first oral treatment for anemia in thalassemia, an inherited blood disorder. News, Events, and Human Drugs. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-oral-treatment-anemia-thalassemia-inherited-blood-disorderLinks to an external site.

Are you struggling to create a sound and comprehensive nursing paper? Do you feel overwhelmed with the amount of time and effort it takes to write a good piece? Are you looking for the best nursing paper writing service that can assist you in your nursing paper needs? Look no further than our skilled team of professional writers who specialize in providing high-quality papers with the best nursing paper writing services reviews. Make your order at nursingpaperhelp.com